If approved, Hetero Biopharma will be the first company to receive approval for the generic version. “The company will present the data of ...

The approval is for the export of up to 8 crore doses of Sputnik Light and up to 2 crore doses of Sputnik V Component I vaccines, Wockhardt...

"We feel confident that Sputnik Light is not only effective against other variants of concern, but also with Omicron,” MV Ramana, CEO, Bran...

Sputnik V in a statement on Thursday said that as per an independent comparative study conducted by the Spallanzani institute in Italy, its...

Sputnik V is a two-dose vaccine made from two components - recombinant adenovirus 26 or Ad26 and adenovirus 5 or Ad5 The first dose (Ad26) ...

Gamaleya said it expects Sputnik V to provide a strong defence against severe disease and hospitalisation, as the drop in neutralising acti...

The drug maker said it is in the midst of finalising the protocol to begin the trials on children and adolescents which will have two cohor...

As per RDIF, Sputnik Light has been authorized in more than 15 countries. Gland Pharma said it is focusing on rolling out the single shot S...

After launching Sputnik V, Russia introduced a new single-dose vaccine, called Sputnik Light, in May. As in the case of Sputnik, Sputnik Li...

The government initiated this review as local manufacturers are facing challenges in producing the second dose of the vaccine — unlike in o...

There has been a delay of 5-6 weeks due to the situation in Russia but the authorities hope that the process will smoothen by August-end or...

An application seeking regulatory approval for Sputnik Light is expected to be filed in the next couple of weeks and it could become the fi...

The company has entered into a three-year agreement with Dr Reddy's Laboratories Limited (DRL) for the production of Sputnik V vaccine for ...

"The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr...

“The committee has asked the company to come back with immunogenicity data,” a government official said, asking not to be identified. Dr Re...

The Hyderabad-headquartered company, which had entered into a partnership with the Russian Direct Investment Fund (RDIF) last September to ...

“The Indian clinical trial being conducted by Dr Reddy’s and RDIF is an adaptive design phase 2/3 trial. It is a bridging study to the larg...